NICN2P

Across TCGA pan-cancer cohorts, NICN2P RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NICN2P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where NICN2P RNA is repressed in tumor relative to normal tissue. In most cancer types NICN2P is over-expressed in tumor, although a few such as BRCA and THCA show the opposite, repressed pattern.

BRCA, COAD, and THCA are the cancer types where NICN2P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NICN2P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.025	.022	4	view →
COAD	Female	II,III,IV	+0.123	.033	2	view →
THCA	All	All	−0.043	.024	2	view →
KIRC	All	II,III,IV	−0.020	.042	1	view →
LUAD	All	All	−0.019	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NICN2P–BRCA

Open the BRCA breakdown →